Sophiris Bio Return on Equity

Sophiris Bio (SPHS) currently reports a ROE of -297.79%. That is below the Healthcare sector average of -75.84%. Use the charts on this page to explore Sophiris Bio's ROE history and peer comparisons.

Sophiris Bio's ROE of -297.79% is lower than the Healthcare sector average of -75.84%. That is roughly 292.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sophiris Bio's current -297.79% should be judged against Healthcare norms (sector average: -75.84%) and against SPHS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -297.79%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Sophiris Bio, and consider following SPHS for alerts when major investors trade the stock.

Sophiris Bio is classified in the Healthcare sector. On ROE, it currently shows -297.79% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPHS with unrelated industries.